Relevant bibliographies by topics / Autologous HSCT

Contents

  1. Journal articles
  2. Books
  3. Book chapters
  4. Conference papers

Academic literature on the topic 'Autologous HSCT'

Author: Grafiati
Published: 7 June 2025
Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Autologous HSCT.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Autologous HSCT"

1

Khalid Ahmed, Al-Anazi, E. Mutahar, O. Abduljalil, et al. "The outcome of autologous hematopoietic stem cell transplantation in patients with multiple myeloma. The experience of King Fahad Specialist Hospital in Dammam, Saudi Arabia." Journal of Stem Cell Therapy and Transplantation 6, no. 1 (2022): 019–28. http://dx.doi.org/10.29328/journal.jsctt.1001027.

Full text
Abstract:
Background: Aautologous hematopoietic stem cell transplants (HSCT) is the standard of care for newly diagnosed patients with multiple myeloma (MM) who are eligible for autologous transplantation. Although cryopreservation is routinely employed, autologous HSCT can be performed using non-cryopreserved stem cells. Methods and materials: A retrospective study of patients with MM who received autologous HSCT between the 10th of October 2010 and the 31st of January 2022 at King Fahad Specialist Hospital (KFSH) in Dammam, Saudi Arabia was performed. Results: Over 11 years and 113 days, a total of 13
APA, Harvard, Vancouver, ISO, and other styles
2

Gratwohl, Alois, Helen Baldomero, Bruno Horisberger, Caroline Schmid, Jakob Passweg, and Alvaro Urbano-Ispizua. "Current trends in hematopoietic stem cell transplantation in Europe." Blood 100, no. 7 (2002): 2374–86. http://dx.doi.org/10.1182/blood-2002-03-0675.

Full text
Abstract:
Major changes have occurred in the transplantation of hematopoietic stem cells (HSCs) during the last decade. This report reveals the changes, reflects current status, and provides medium-term projections of HSC transplantation (HSCT) development in Europe. Data on 132 963 patients, 44 165 with allogeneic HSC transplant (33%) and 88 798 with an autologous HSC transplant (67%), collected prospectively from 619 centers by the European Group for Blood and Marrow Transplantation (EBMT) in 35 European countries between 1990 (4234 HSCTs) and 2000 (19 136 HSCTs) illustrate utilization of HSCT. HSCT i
APA, Harvard, Vancouver, ISO, and other styles
3

Khalid Ahmed, Al-Anazi, A. Alshami, E. Mutahar, et al. "Outcome of Outpatient Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma and Relapsed and Refractory Hodgkin Lymphoma. The Experience of King Fahad Specialist Hospital in Dammam, Saudi Arabia." Journal of Stem Cell Therapy and Transplantation 7, no. 1 (2023): 003–15. http://dx.doi.org/10.29328/journal.jsctt.1001030.

Full text
Abstract:
Background: Autologous hematopoietic stem cell transplants (HSCT) is the standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (MM) and patients with relapsed and refractory Hodgkin lymphoma (R/R-HL) who achieve chemosensitivity after salvage therapy. Although autologous HSCT is routinely performed in an inpatient setting, the procedure can safely be performed in an outpatient setting. Methods and materials: A retrospective study of patients with MM and R/R- HL who received outpatient autologous HSCT at King Fahad Specialist Hospital (KFSH) in Dammam, Saudi Ar
APA, Harvard, Vancouver, ISO, and other styles
4

Rowe, Jacob M., Zhuoxin Sun, Peter A. Cassileth, et al. "Treatment-Related Mortality and Relapse Rate from Time of Initiation of Post-Remission Therapy for Patients Receiving Allogeneic Transplantation, Autologous Transplantation or Intensive Chemotherapy: A Report from the Eastern Cooperative Oncology Group (ECOG)." Blood 112, no. 11 (2008): 49. http://dx.doi.org/10.1182/blood.v112.11.49.49.

Full text
Abstract:
Abstract Over the past decade several prospective studies of post-remission therapy in AML have compared allogeneic hematopoietic stem cell transplantation (HSCT), autologous HSCT and chemotherapy. The data are appropriately presented by intention-to-treat analyses. However, such analyses do not provide information to the clinician or patient as to outcome from the initiation of post-remission therapy, be it HSCT or chemotherapy. Furthermore, such analyses are impossible to interpret when a significant percentage of patients do not receive their intended therapies (for example, only 54% of pat
APA, Harvard, Vancouver, ISO, and other styles
5

Snowden, John A. "Rebooting autoimmunity with autologous HSCT." Blood 127, no. 1 (2016): 8–10. http://dx.doi.org/10.1182/blood-2015-11-678607.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Verrecchia, Franck, and Dominique Farge. "Autologous HSCT: toward scleroderma treatment." Blood 110, no. 4 (2007): 1088–89. http://dx.doi.org/10.1182/blood-2007-05-089102.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

van Laar, Jacob M., Svetlana I. Nihtyanova, Kamran Naraghi, Christopher P. Denton, and Alan Tyndall. "Autologous HSCT for systemic sclerosis." Lancet 381, no. 9883 (2013): 2079–80. http://dx.doi.org/10.1016/s0140-6736(13)61239-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Sakellari, Ioanna, Eleni Gavriilaki, Despoina Mallouri, Ioannis Batsis, and Achilles Anagnostopoulos. "Autologous HSCT for systemic sclerosis." Lancet 381, no. 9883 (2013): 2080. http://dx.doi.org/10.1016/s0140-6736(13)61240-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kohn, Donald B. "Eliminating SCID row: new approaches to SCID." Hematology 2014, no. 1 (2014): 475–80. http://dx.doi.org/10.1182/asheducation-2014.1.475.

Full text
Abstract:
Abstract Treatments for patients with SCID by hematopoietic stem cell transplantation (HSCT) have changed this otherwise lethal primary immune deficiency disorder into one with an increasingly good prognosis. SCID has been the paradigm disorder supporting many key advances in the field of HSCT, with first-in-human successes with matched sibling, haploidentical, and matched unrelated donor allogeneic transplantations. Nevertheless, the optimal approaches for HSCT are still being defined, including determining the optimal stem cell sources, the use and types of pretransplantation conditioning, a
APA, Harvard, Vancouver, ISO, and other styles
10

BOHGAKI, TOSHIYUKI, TATSUYA ATSUMI, MIYUKI BOHGAKI, et al. "Immunological Reconstitution after Autologous Hematopoietic Stem Cell Transplantation in Patients with Systemic Sclerosis: Relationship Between Clinical Benefits and Intensity of Immunosuppression." Journal of Rheumatology 36, no. 6 (2009): 1240–48. http://dx.doi.org/10.3899/jrheum.081025.

Full text
Abstract:
Objective.To analyze the relationship between clinical benefits and immunological changes in patients with systemic sclerosis (SSc) treated with autologous hematopoietic stem cell transplantation (HSCT).Methods.Ten patients with SSc were treated with high-dose cyclophosphamide followed by highly purified CD34+ cells (n = 5) or unpurified grafts (n = 5). Two groups of patients were retrospectively constituted based on their clinical response (good responders, n = 7; and poor responders, n = 3). As well as clinical findings, immunological reconstitution through autologous HSCT was assessed by fl
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Autologous HSCT"

1

Wingard, John R. Introduction. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199938568.003.0300.

Full text
Abstract:
This chapter starts by explaining that the goal of allogeneic stem cell transplantation is the establishment of donor hematopoiesis and immunity in the recipient to treat an antecedent marrow failure disorder or to achieve a graft-versus-cancer effect to treat a neoplastic disease. The goal of autologous hematopoietic stem cell transplant (HSCT) is very different from allogeneic HSCT. In autologous HSCT, the goal of the graft is simpler: it is to rescue the myelotoxic effects of high-dose chemotherapy. Neutropenia is shorter, cellular immunodeficiency is less profound, and immune reconstitutio
APA, Harvard, Vancouver, ISO, and other styles
2

Tyndall, Alan, and Jacob M. van Laar. Stem cell therapies. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0085.

Full text
Abstract:
Since the start of the international project in 1997, over 1500 patients have received a haematopoietic stem cell transplant (HSCT), mostly autologous, as treatment for a severe autoimmune disease, with overall 85% 5-year survival and 43% progression-free survival. Around 30% of patients in all disease subgroups had a complete response, often durable despite full immune reconstitution. In many cases, e.g. systemic sclerosis, morphological improvement such as reduction of skin collagen and normalization of microvasculature was documented, beyond any predicted known effects of intense immunosupp
APA, Harvard, Vancouver, ISO, and other styles
3

Tyndall, Alan, and Jacob M. van Laar. Stem cell therapies. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199642489.003.0085_update_003.

Full text
Abstract:
Since the start of the international project in 1997, over 2000 patients have received a haematopoietic stem cell transplant (HSCT), mostly autologous, as treatment for a severe autoimmune disease, with overall 85% 5-year survival and 43% progression-free survival. Around 30% of patients in all disease subgroups had a complete response, often durable despite full immune reconstitution. In many cases, e.g. systemic sclerosis, morphological improvement such as reduction of skin collagen and normalization of microvasculature was documented, beyond any predicted known effects of intense immunosupp
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Autologous HSCT"

1

Richter, Darko. "Requiring Immunization After Rescue Autologous HSCT." In Pediatric Autoimmunity and Transplantation. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-26280-8_48.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Galgano, Letizia, Daphna Hutt, and Hilda Mekelenkamp. "HSCT: How Does It Work?" In The European Blood and Marrow Transplantation Textbook for Nurses. Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-23394-4_2.

Full text
Abstract:
AbstractThe HSCT (haematopoietic stem cell transplant) is a particular treatment for many haematological and non-haematological diseases. Broadly, there are three different categories of transplantation, autologous, allogeneic and syngeneic, which can be applied to most disease scenarios. Haematopoietic stem cells can be derived from the bone marrow, peripheral blood and umbilical cord blood. HSCT treatment can be divided into separate phases that start with the harvest of the stem cells and passing through the conditioning, aplasia and engraftment until the recovery of the haematopoietic func
APA, Harvard, Vancouver, ISO, and other styles
3

Burt, Richard K., Dominique Farge, Riccardo Saccardi, Kathleen Quigley, Xiaoqiang Han, and John A. Snowden. "Autologous HSCT Conditioning Regimens for Autoimmune Diseases." In Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases. CRC Press, 2021. http://dx.doi.org/10.1201/9781315151366-24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Jing, Weiqing, and Bryon D. Johnson. "Tumor Vaccination after Autologous HSCT: What has been Learned from Experimental Models." In Cancer Vaccines and Tumor Immunity. John Wiley & Sons, Inc., 2007. http://dx.doi.org/10.1002/9780470170113.ch13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Worel, Nina, Yavuz M. Bilgin, and Patrick Wuchter. "Mobilization and Collection of HSC." In The EBMT Handbook. Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-44080-9_16.

Full text
Abstract:
AbstractThe intravenous infusion of patient’s own HSC (autologous SCT) to restore BM damage is the basic principle of high-dose chemotherapy, since otherwise the patient would expect long-lasting aplasia with life-threatening infections. Therefore, a sufficient collection of HSC before application of high-dose therapy is mandatory. Since HSC expresses CD34 on their surface, the number of CD34+ cells in the transplant material is considered as an indicator of the HSC content.The aim of infusion of HSC from a donor (allogeneic SCT) is to restore BM damage and to treat the patient’s disease. It r
APA, Harvard, Vancouver, ISO, and other styles
6

Wuchter, Patrick. "Processing, Cryopreserving, and Controlling the Quality of HSC." In The EBMT Handbook. Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-44080-9_20.

Full text
Abstract:
AbstractThe efficiency of an autologous, as well as an allogeneic, HSC graft is mainly determined by the number of CD34+ cells present. The dose of transplanted CD34+ cells per kg body weight (bw) determines the kinetics of the neutrophil and platelet engraftment after auto-HCT (Weaver et al. Blood 86:3961–9, 1995). The measurement of CD34+ cells by flow cytometry is, therefore, an important method to assess the graft quantity and quality.
APA, Harvard, Vancouver, ISO, and other styles
7

Ryzhak, O., S. Donska, J. Bazaluk, and N. Genkina. "Autologous Transplantation of Non-Cryopreserved HSCs in Oncologic Patients with Poor Prognosis: First Experience in the Ukraine." In Transplantation in Hematology and Oncology II. Springer Berlin Heidelberg, 2003. http://dx.doi.org/10.1007/978-3-642-55774-3_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

A. Al-Anazi, Khalid, Ziyad Alshaibani, and Panagiotis Kalogianidis. "An Update on Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma." In Recent Update on Multiple Myeloma [Working Title]. IntechOpen, 2023. http://dx.doi.org/10.5772/intechopen.109059.

Full text
Abstract:
Over the past two decades, treatment of multiple myeloma (MM) has advanced dramatically. However, despite the introduction of several lines of novel therapeutics, autologous hematopoietic stem cell transplantation (HSCT) followed by maintenance therapy is the current standard of care in transplant eligible patients. Autologous HSCT can be performed with or without cryopreservation with equivalent short-term and long-term outcomes. In patients with MM, performance of autologous HSCT at outpatient setting is safe, feasible and has a number of advantages such as saving hospital beds and reducing
APA, Harvard, Vancouver, ISO, and other styles
9

Bories, Mathilde, Aurélie Bannay, Morgane Pierre-Jean, Guillaume Bouzille, and Pascal Le Corre. "Measurement of Cumulative Drug Exposure from Clinical Data Warehouse." In Studies in Health Technology and Informatics. IOS Press, 2024. http://dx.doi.org/10.3233/shti241085.

Full text
Abstract:
Polypharmacy (PP) and hyperpolypharmacy (HPP), are prevalent among cancer patients and are associated with an increased risk of drug-drug interactions (DDI) and potentially inappropriate medications (PIM). This study aimed to characterize PP, HPP, DDI, and PIM in patients with hematological malignancies hospitalized for hematopoietic stem cell transplantation (HSCT) by introducing a novel metric: cumulative drug exposure. Clinical data warehouse (CDW) records were employed to develop algorithms that quantified patients’ cumulative exposure to these prescribing determinants during hospitalizati
APA, Harvard, Vancouver, ISO, and other styles
10

Silva, Kayane Nascimento da, Maria Yasmin Paz Teixeira Martins, Ana Filomena Camacho Santos Daltro, et al. "Overweight and cardiovascular risk in patients undergoing hematopoietic stem cell transplantation." In A LOOK AT DEVELOPMENT. Seven Editora, 2023. http://dx.doi.org/10.56238/alookdevelopv1-123.

Full text
Abstract:
Introduction: Hematopoietic Stem Cell Transplantation (HSCT) is a therapeutic proposal for oncohematological treatment that includes the use of high-dose chemotherapy, after carrying out the conditioning regimen, and many of these classes of antineoplastic agents have cardiotoxic effects. In addition, cardiovascular diseases are among the main causes of post-HSCT morbidity and mortality. Objectives: To assess the nutritional status and cardiovascular risk of patients admitted for HSCT. Methods: Cross-sectional, retrospective study with an analytical component and a quantitative approach. Data
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Autologous HSCT"

1

Gee, A. P. "Hematopoietic Stem Cell Engineering: The Magic Bullet of the Next Millenium?" In ASME 1997 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 1997. http://dx.doi.org/10.1115/imece1997-1317.

Full text
Abstract:
Abstract Hematopoietic stem cell [HSC] therapy has its origins as hematological rescue following marrow ablative high-dose therapy for refractory cancers and myelodysplastic syndromes. In its simplest form, bone marrow is collected from a tissue-matched related normal donor and intravenously infused into the patient who has usually received high-dose chemo/radiotherapy for his or her disease. The stem cells migrate to the marrow spaces, where they multiply and differentiate to restore blood cell-forming activity and immune defenses in the recipient Restrictions in the availability of tissue-ma
APA, Harvard, Vancouver, ISO, and other styles
2

Alexander, T., C. Samuelson, T. Daikeler, et al. "SAT0549 Autologous hematopoietic stem cell transplantation (HSCT) for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) – a ebmt retrospective survey." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.7404.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Khoury, H., and R. Burt. "AB0766 Initial characterisation of women with breast implants in a group of patients with systemic sclerosis referred for autologous HSCT." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.1092.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lee, Daniel W., Nirali Shah, Maryalice Stetler-Stevenson, et al. "Abstract LB-138: Autologous-collected anti-cd19 chimeric antigen receptor (CAR) T cells for acute lymphocytic leukemia (ALL) and Non-Hodgkin's lymphoma (NHL) in children who have previously undergone allogeneic hematopoietic stem cell transplantation (HSCT)." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-lb-138.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Farge, DC, S. Zohar, MH Andre, et al. "OP0038 Autologous hematopoietic stem cells (hsc) transplantation in scleroderma and myositis." In Annual European Congress of Rheumatology, Annals of the rheumatic diseases ARD July 2001. BMJ Publishing Group Ltd and European League Against Rheumatism, 2001. http://dx.doi.org/10.1136/annrheumdis-2001.295.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Autologous HSCT' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography